{"schema_version":"secwatch.filing_event.v1","accession":"0001613103-23-000144","form_type":"8-K","ticker":"MDT","cik":"0001613103","company_name":"Medtronic plc","filed_at":"2023-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.778586+00:00","generated_at":"2026-06-07T22:41:36.964339+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Medtronic Q2 FY24 revenue up 5.3% to $7.984B; GAAP EPS $0.68, non-GAAP $1.25; raises FY24 guidance","bullets":["Revenue $7.984B, +5.3% reported / +5.0% organic; GAAP net income $909M ($0.68 EPS) +113%; non-GAAP EPS $1.25.","Cardiovascular revenue $2.923B (+5.9%); Neuroscience $2.288B (+4.7%); Medical Surgical $2.142B (+7.0%); Diabetes $610M (+9.7%).","Raises FY24 organic revenue growth guidance to 4.75% (from 4.5%) and non-GAAP EPS guidance to $5.13–$5.19 (from $5.08–$5.16).","FDA approvals for Aurora EV-ICD and Symplicity Spyral RDN; CE Marks for Evolut FX TAVR, Simplera CGM, PulseSelect PFA."],"urls":{"canonical":"https://secwatch.observer/filing/0001613103-23-000144","json":"https://secwatch.observer/filing/0001613103-23-000144.json","markdown":"https://secwatch.observer/filing/0001613103-23-000144.md","text":"https://secwatch.observer/filing/0001613103-23-000144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613103/000161310323000144/0001613103-23-000144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613103/000161310323000144/mdt-20231121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:41:36.964339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b4fb60b46092efb59b1fc853bdc099c86d09f9d","claim":"Medtronic plc reported second quarter of fiscal year 2024 results: revenue Revenue of $8.0 billion. Guidance raised.","evidence_excerpt":"2023 – Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key Highlights • Revenue of $8.0 billion increased 5.3% as reported and 5.0% organic • GAAP diluted earnings per share (EPS) of $0.68; non-GAAP diluted EPS of $1.25 • Underlying business fundamentals are strong with","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310323000144/0001613103-23-000144-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of fiscal year 2024"},{"label":"Revenue","value":"Revenue of $8.0 billion"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}